Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BIIB

Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of $31.20 billion.

Benzinga

3 Biotech Stocks to Buy Now

Biotech stocks are starting to move higher as longer-term rates decline. The sector is very cheap with strong long-term fundamentals. Amgen (AMGN), Biogen (BIIB), and Bio-Techne (TECH) are 3 top biotech stocks that investors should consider buying.

StockNews.com

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of $30.05 billion.

Benzinga

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.1% on an annualized basis producing an average annual return of 10.04%. Currently, Biogen has a market capitalization of $29.43 billion.

Benzinga

3 Buy-Rated Biotechs to Buy in May

Despite logistical hurdles, the biotech industry is expected to expand solidly in the coming years on lucrative federal investments and strong demand. Therefore, we think it could be wise to bet on the stocks of quality biotech companies Biogen (BIIB), BioNTech (BNTX), and Incyte (INCY). These stocks are rated ‘Buy’…

StockNews.com

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Read Why Biogen Shares Are Trading Higher After Q1 Earnings

Biogen Inc (NASDAQ:BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 billion decreased by 3%. Spinraza's revenue of $441 million decreased 9% at actual currency and 6% at constant currency. Aduhelm's revenue was…

Benzinga

Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module and plan to submit the remaining…

Benzinga

Why This Analyst Believes Biogen Is 'Too Good to Ignore'

Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which contributes 15% of current revenues and 40% of the valuation, according to Wells Fargo.

Benzinga

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

Benzinga

5 Wildly Undervalued Large-Cap Stocks to Buy Now

Amid current market volatility that is being fueled by investors' anticipation of aggressive interest rate increases this year, rising inflation, economic sanctions on Russia in response to Russia’s invasion of Ukraine, and surging oil prices, investors are seeking investment opportunities in undervalued large-cap companies to generate relatively stable returns. Thus,…

StockNews.com

Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab

In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have

Benzinga

3 Wide-Moat Stocks That Look Cheap: Biogen, Medtronic, and Bristol-Myers Squibb

: Major stock indices appear heading for weekly gains with the Fed’s first interest rate hike digested easily by investors. However, the market is expected to remain under pressure in the near term. So, because wide-moat companies generally do well in these market conditions, we think cheap wide-moat stocks Bristol-Myers…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks

Biogen Inc (NASDAQ:BIIB) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid-beta…

Benzinga

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

Benzinga

Biogen Posts New Updates Across its Spinraza SMA Research Program

Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies.

Benzinga

Expert Ratings For Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing

Benzinga

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

Benzinga

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

Benzinga

What 24 Analyst Ratings Have To Say About Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Benzinga

Analyst Ratings For Biogen

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Benzinga

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

Benzinga

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

Biogen Inc (NASDAQ: BIIB) has

1 … 3 4 5 6

People

Mangeet Kaur BounsMangeet

595 stories

Jaimini DesaiJaimini

62 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Federal Trade Commission

186 stories

Securities and Exchange Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.